ロード中...

Pharmacokinetics of Adjusted-Dose Lopinavir-Ritonavir Combined with Rifampin in Healthy Volunteers

Coadministration of lopinavir-ritonavir, an antiretroviral protease inhibitor, at the standard dose (400/100 mg twice a day [BID]) with the antituberculous agent rifampin is contraindicated because of a significant pharmacokinetic interaction due to induction of cytochrome P450 3A by rifampin. In th...

詳細記述

保存先:
書誌詳細
出版年:Antimicrob Agents Chemother
主要な著者: la Porte, C. J. L., Colbers, E. P. H., Bertz, R., Voncken, D. S., Wikstrom, K., Boeree, M. J., Koopmans, P. P., Hekster, Y. A., Burger, D. M.
フォーマット: Artigo
言語:Inglês
出版事項: American Society for Microbiology (ASM) 2004
主題:
オンライン・アクセス:https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC400571/
https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/15105105/
https://ncbi.nlm.nih.govhttps://doi.org/10.1128/AAC.48.5.1553-1560.2004
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!